Latest / Eyewire News: The Podcast

Bayer Acquires Perfuse in $2.45 Billion Deal
Bayer expands ophthalmology pipeline with acquisiton of Perfuse Therapeutics; Viridian announces new phase 3 data for its investigational subcutaneous injection for chronic thyroid eye disease; and Steven Dell, MD discusses the impact of declining reimbursement could on ophthalmic practices.
Learn more about your ad choices. Visit megaphone.fm/adchoices
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.